Oncology Billing Services: Where the Money Leaks in Community Cancer Care

By Medtransic Team | March 8, 2026 | 11 min read | Updated: July 3, 2026

Quick Summary: Community oncology carries more billing risk per encounter than any specialty in medicine: drugs that cost more than cars, an infusion coding hierarchy with exactly one "initial" service per visit, waste rules with teeth, and a diagnosis-coding discipline that decides whether treatment gets covered at all. Here's how the money actually flows through an oncology practice — and where it leaks.

Every billing conversation in oncology eventually arrives at the same fact: the drugs cost more than everything else combined. A community oncology practice running buy-and-bill purchases chemotherapy and immunotherapy agents at prices that dwarf its professional fees, fronts that cost, and recovers it claim by claim on a margin set by formula. That structure makes oncology billing less like other specialties' and more like running a high-stakes logistics operation: the tolerances are tight, the volumes are large, and a single systematic error — wrong units, wrong sequence, lapsed authorization — doesn't cost fees. It costs drug inventory.

This article maps the actual mechanics: the Part B drug margin, the infusion coding hierarchy, the waste rules, the diagnosis discipline, and the model-era wrinkles. It's the same map Medtransic's oncology billing team works from.

• ASP+6% The Statutory Part B Drug Formula - The margin every claim error eats into
• One Initial One Initial Infusion Service Per Day - The hierarchy everything else hangs from
• Waste Rules Waste Attestation, Mandatory - Single-dose vials, since July 2023
• Dx First Chemo Encounter Diagnosis - Sequenced first on treatment visits

The Drug Economics That Rule Everything

Buy-and-bill oncology works on a formula: Medicare Part B pays for physician-administered drugs at the manufacturer's average sales price plus a statutory add-on of 6% (reduced in practice by budget sequestration). The formula is public, the margin is thin, and the acquisition cost is enormous — which produces oncology's defining billing math: the professional services on an infusion day are a rounding error next to the drug line. A practice can code every office visit perfectly and still bleed out through drug-line errors, because that's where the money is.

Commercial payers complicate the picture in both directions — negotiated drug rates, mandatory specialty-pharmacy "white bagging" for some plans (which removes both the cost and the margin from the practice), and site-of-service steering. An oncology practice should have, and its billing partner should maintain, a per-payer picture of what each major regimen actually nets. Regimens that lose money at acquisition-versus-reimbursement deserve a deliberate decision, not accidental discovery.

The Infusion Hierarchy: One Initial Service Per Day

A chemotherapy day generates a stack of administration services — the primary agent, sequential drugs, supportive medications, hydration — and the coding rules price the stack through a hierarchy with one iron rule: a single "initial" service per encounter. Chemotherapy outranks therapeutic infusions, which outrank hydration; the first hour of the chemo infusion is the initial service, additional hours bill separately, each additional drug bills as a sequential administration, and hydration bills only when it's a distinct, medically necessary service rather than the fluid the drugs rode in on.

• Two "initial" services on one claim — the classic edit-triggering error when supportive infusions get coded as if they stood alone.
• Missing sequential drugs — the mirror error: pre-medications and secondary agents administered, documented, and never billed.
• Hours without times — additional-hour charges are only as defensible as the documented start and stop times; missing times mean either underbilled hours or unsupportable claims.
• Hydration billed reflexively — payable when distinct and necessary, denied (or worse, patterned into an audit) when billed on every encounter by default.

The infusion suite's nursing documentation is, in a literal sense, the billing system. Practices that align their infusion charting — times, drugs, volumes, waste — with the coding hierarchy collect what the hierarchy allows. Practices that don't are guessing, in both directions, on every treatment day.

Units and Waste: Where Audits Are Born

Oncology drug claims run on billing units that rarely match vials or milligrams one-to-one, and doses are body-surface-area or weight-based — so every claim is an arithmetic exercise: dose administered, converted to billing units, reconciled against vials opened. Get the conversion wrong and the claim either donates most of the drug or overbills into an audit. Layered on top since July 2023 is the waste-attestation regime: single-dose-vial claims must either report discarded drug on a separate waste-reporting line (which is payable — waste properly documented is revenue, not just compliance) or carry a no-waste attestation. Neither is optional, and unit totals that can't reconcile against real vial sizes are exactly what payer integrity software is built to flag.

Diagnosis Discipline: The Coding That Justifies Treatment

Oncology's diagnosis coding does more work than almost any other specialty's, because payer medical policies key coverage of specific drugs to specific malignancies, stages, and biomarkers. The mechanical rule everyone learns first: on encounters whose purpose is chemotherapy administration, the chemotherapy-encounter diagnosis is sequenced as the first-listed diagnosis, with the malignancy coded behind it — at full specificity: site, laterality, histology where the code set provides it, and the distinction between active disease, secondary sites, and personal history once treatment concludes. Coding a historical cancer as active misstates the clinical picture; coding an active cancer as history can cut off coverage for ongoing treatment. And as targeted therapies tie coverage to biomarkers, the documentation supporting the diagnosis increasingly has to include the pathology and molecular results the payer's policy names.

Beyond the Chair: Trials, Orals, and the EOM Era

Three more structures shape oncology revenue outside the infusion chair. Clinical trials: patients on trials still generate billable routine care, but the claims must separate routine costs (billable to insurance, with trial-designation flags and the trial's identifiers where required) from sponsor-paid items — a segregation problem that produces both false claims risk and donated care when handled sloppily. Oral oncolytics: as therapy shifts oral, revenue shifts from Part B buy-and-bill to pharmacy benefits, and practices with medically integrated dispensing take on an entirely separate billing discipline. Value-based models: the Enhancing Oncology Model — CMS's successor to the Oncology Care Model, running since July 2023 — pays participating practices episode-based amounts tied to quality and total-cost accountability, which makes clean, complete claims data not just a revenue matter but the practice's performance record in the model.

What to Ask an Oncology Billing Partner

The stakes justify a demanding interview:

1. Walk me through your pre-submission reconciliation on a chemo claim: dose to units, vials to waste lines, times to hours, authorization to regimen. Which are checked on every claim?
2. How do you enforce the one-initial-service hierarchy — and when did you last find a two-initial claim before the payer did?
3. Show me how your waste-attestation compliance works in your workflow, starting from nursing documentation.
4. Who maintains the authorization ledger against the treatment calendar, and how are mid-course regimen changes caught?
5. Can you produce per-payer, per-regimen margin analysis — acquisition cost versus actual reimbursement?
6. How do you segregate clinical trial claims, and have you billed under the Enhancing Oncology Model?

Oncology billing is unforgiving because the numbers are large and the rules are exact — which is also why it rewards specialization more than any other specialty. Medtransic's oncology billing program runs the reconciliations above as standard practice, with prior authorization support and denial management integrated. Practices running biologic infusions outside oncology face the same buy-and-bill drug mechanics we cover in our rheumatology billing guide. Request a billing review and we'll audit your infusion claims — units, hierarchy, waste, and authorizations — line by line.

Sources & References

• CMS — Medicare Part B drug payment (ASP methodology and pricing files)
• CMS — discarded drug waste-attestation requirements
• CMS Innovation Center — Enhancing Oncology Model
• AMA — drug administration coding hierarchy